bioMérieux

bioMérieux is a multinational biotechnology company headquartered in France that focuses on in vitro diagnostics. The company develops and sells reagents, instruments, and software solutions used for clinical microbiology, immunoassay testing, and molecular biology applications. Its products are designed to detect infectious diseases, antimicrobial resistance, and various biomarkers in patient samples. bioMérieux also provides diagnostic systems for industrial sectors such as food safety, pharmaceutical manufacturing, and environmental monitoring. The company serves hospitals, clinical laboratories, research institutions, and industrial clients across the globe. Its offerings are intended to support timely diagnosis and inform treatment or process decisions.

bioMérieux maintains a worldwide presence with operations and distribution networks in numerous countries, reflecting its global market reach. The company is publicly listed on the Euronext Paris exchange and is majority‑owned by Institut Mérieux, a family‑held holding group. Its distinguishing attributes include a long‑standing specialization in microbiology and a reputation for high‑quality, regulatory‑compliant diagnostic products. bioMérieux invests in research and development to advance technologies such as syndromic testing and automation in laboratory workflows. In June 2023, the company disclosed a cybersecurity incident involving a vendor, Vitality Group, that led to the unauthorized release of personal data including social security numbers and health information; the breach did not affect its internal systems and data sharing with the vendor was suspended pending investigation. This incident highlights the organization’s exposure to third‑party risk while underscoring its commitment to transparency and remedial action.